OMVs engineered to display a ClyA‐HER2 targeting probe were able to target cells over‐expressing HER2, a common biomarker of cancer cells, and induce cell death and tumor shrinkage via the delivery of siRNA targeting the expression of kinesin spindle protein (Gujrati et al., 2014). The gene discussed is PROS1; the disease is neoplasm.